Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
Alliance Foundation Trials, LLC.
Study ID
NCT07149363
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Small Cell Lung Cancer (SCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab 50 MG/ML — DRUG
    Following surgical removal of their small-cell lung cancer, participants will receive a combination of 1500 mg durvalumab and cisplatin 75 mg/m2 or carboplatin AUC 5 on day 1, and etoposide 100 mg/m2 on days 1, 2, and 3, every 3 weeks for 4 cycles (a total of 12 weeks). Following the combination of chemotherapy and immunotherapy, participants will then receive 1500 mg durvalumab every 4 weeks for 9 cycles (a total of 36 weeks).

Study Details

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

Key Dates

Start date
Feb 28, 2026
Status verified
Feb 2026
Primary completion
Feb 28, 2029
Completion
Feb 28, 2031

Study Design

Enrollment
65 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab and one of the two chemotherapy combinations: cisplatin or carboplatin, and etoposide
    65 participants will be enrolled.

Primary Outcome Measure

Disease free survival (DFS) [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Virginia Comprehensive Cancer CenterCharlottesvilleVirginia22908-

Find similar trials in Charlottesville, VA

By research site
University of Virginia Comprehensive Cancer Center· Charlottesville, VA

Related Studies